The medical use of ketamine to alleviate symptoms of depression carries a low risk of addiction, suggests new research from the University of Geneva (UNIGE).
Biopharmaceutical company Silo Pharma has carried out an animal study investigating the topical administration of ketamine for pain reduction.
The UK’s national innovation agency – Innovate UK – has provided funding to Awakn Life Sciences to help bring its ketamine-assisted therapy to alcohol use disorder...
A new study has revealed how ketamine works, which scientists say paves the way toward the development of safe, effective treatments for depression.
The first patient has been dosed in HMNC and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study.
A new study from Northwestern Medicine has identified for the first time how ketamine works so quickly, and how it might be adapted for use as...
Awakn Life Sciences will be carrying out a follow-on behavioural study to focus on gambling disorder following its recent successful pilot study and patent filing.
Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy.
Awakn Life Science’s study exploring the use of ketamine as a treatment for Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior is...
Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.